Walgreen co
1 / 30

WALGREEN CO. - PowerPoint PPT Presentation

  • Uploaded on

WALGREEN CO. Matt Byford Brandon Honey Shivam Khanna Joe Vaccaro October 28, 2008. Agenda. Company Overview Macroeconomic Overview Industry Overview Recent Developments Forecasting/Expectations Valuation of Walgreens Recommendation. Company Overview.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'WALGREEN CO.' - muriel

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Walgreen co


Matt Byford

Brandon Honey

Shivam Khanna

Joe Vaccaro

October 28, 2008


  • Company Overview

  • Macroeconomic Overview

  • Industry Overview

  • Recent Developments

  • Forecasting/Expectations

  • Valuation of Walgreens

  • Recommendation

Company overview
Company Overview

  • Founded in 1901 by Charles Walgreen

    • 1st store was in Chicago

  • 226,000 employees as of 8/31/2007

  • Goal is to have 7,000 stores open by 2009

Company overview1
Company Overview

Walgreen company operates retail drug store chains that are engaged in the retail sale of prescription drugs, non-prescription drugs, and general merchandise.

In 2008, it opened 561 net new stores for a total of 6443 Walgreens in 49 states, District of Columbia, and in Puerto Rico.

It is the fastest growing retailer in the US, and is the 2nd largest drugstore chain behind CVS.

Ranked 44th on the Fortune 500 list of the largest US-based companies.

On the list of Fortune’s magazine’s Most Admired Companies in America for the last 14 consecutive years.

Company overview2
Company Overview

  • A.G. McNally

    • Chairman of the Board since 2008

    • Chief Executive Officer since 2008

    • Board member sine 1999

  • Gregory Wasson

    • President and Chief Operating Officer since 2007

  • Jeff Rein retired in October 2008

    • Chairman and Chief Executive officer since 2003

  • William Rudolphsen

    • Senior Vice President and Chief Financial Officer since 2004, new role as Chief Risk Officer

      • Has been with Walgreens since 1977

Walgreen co

Macroeconomic Overview

Decline in Consumer Confidence

CCI hit all time low in June 2008 (51)

Macroeconomic overview
Macroeconomic Overview

  • Oil continues to be volatile, but lower prices will have positive impact on economy

  • Cost to do business will be lower


  • Organic store growth

    • Relocate, remodel

    • Densely-populated areas like Southern California and Northeast

  • Invest heavily in high-tech store and distribution systems which drive service up and costs down

  • Acquisitions where there are synergies

  • Healthcare offerings beyond that of a traditional pharmacy

    • Offer an online drugstore web site totally integrated with retail stores

    • Take Care Healthcare Systems

  • Increase market share in front-end of stores

  • Must continue to find ways to leverage the benefits of scale without losing the ability to react quickly to changes in customer needs

  • Strategy1

    • Growth

      • Walgreens is currently increasing their net stores operated by approximately 1 store every 16 hours

      • The company, which currently operates 6,443 stores, plans to operate at least 7,000 stores by 2009

        • See room for organic growth to 13,000 stores


    • Introduced freestanding stores in early 1990s with drive thru pharmacies

      • Today, more than 80% of Walgreen Co.’s stores have drive thru pharmacies

  • Nation-wide 1 hour photo service

    • Available at more than 98% of stores

  • Touch tone prescription refills

  • 50% of people live within 2 miles of a Walgreens

  • Drug store industry
    Drug Store Industry

    • Highly Competitive Industry

      • Competition with other drugstore chains, independent drugstores, mail order prescription providers, internet pharmacies

      • Other competitors include various grocery stores, mass merchants, and dollar stores

    • Main competitors:

      • CVS Corp. (CVS)

      • Rite Aid Corp. (RAD)

      • Wal-Mart (WMT)

        • Pharmaceutical more than grocery department

        • Now offers a $4 generic prescription plan

      • Drugstore.com

    Rcmp position
    RCMP Position

    • Own 500 shares in Walgreens

    • Purchased at $25/share on 10/06/1999

    • Sold 500 shares at $49.94/share on 9/14/2006

    • Cost Basis is $12,500

    • Stock is now trading at $21.40/share

      • Valued at $10,700

  • Represents 2.4% of portfolio market value

  • Unrealized Loss of $1,800 or 14.4%

  • Shareholder base
    Shareholder Base

    • 67% of shares owned by institutional investors

    • 125,000 shares sold by insiders in last 6 months





    Home infusion

    Therapy provider







    Take care



    Product class
    Product class

    Prescription sales continue to become a larger portion of the company’s business.

    Aging population

    Introduction of lower priced generics (Medicare D)

    R&D of innovative drugs

    Walgreen outlook
    Walgreen Outlook

    • Advantages:

      • Good reputation / quality

      • Convenience of locations: High market share

      • Economies of scale

      • Aging population

    • Risk factors:

      • Peaking generic drug cycle:

      • Store saturation/cannibalization

      • Competition from CVS/Caremark, Wal-Mart

      • Diverging from original growth strategy

    Porters five forces retail drug industry
    Porters Five Forces: Retail Drug Industry

    • Rivalry: High

      • Competitive Industry

      • Direct mail pharmacy benefit managers

      • Grocery stores & big box retailers

    • Threat of Substitutes: Low

      • Few alternative choices for products sold at Walgreens/Drug Retailers

    • Bargaining Power of Buyers: Moderate

      • Insurance companies

      • Walgreens receives premium prices for front end convenience items

    • Bargaining Power of Suppliers: Moderate

      • Watch government regulations / upcoming election

    • Barriers to Entry: Moderate

      • High initial capital expenditures & supplier relationship required


    Source: Yahoo Finance

    1 yr stock performance
    1 Yr. Stock Performance

    Source: Yahoo Finance

    5 yr stock performance
    5 Yr. Stock Performance

    Source: Yahoo Finance

    Longs bid withdrawal
    Longs Bid Withdrawal

    • Competitive action vs. Failed action

      • Caused CVS to overvalue Longs

      • CVS must pay $71.50 per share

      • Most likely has to access debt

        • Challenging debt market

        • CVS must pay a penalty if it cannot access financing

    Longs bid withdrawal1
    Longs Bid Withdrawal

    • Longs is exposed to the poor condition of the CA market

    • Longs would have few synergies with WAG

    • WAG did not want to risk its credit rating

      • Senior unsecured debt was downgraded anyway from AAA to AA

        • EBIT coverage ratio fell because of increase in LT debt

        • Uncertainty of strategic direction

        • CEO Jeff Rein retired


    • Prescription sales will grow

    • Specialty Pharmacy sales will become a greater part of the business

    • 7000th store will open FY 2009

    • Organic store growth will begin slowing in 2011

      • Increases flexibility

      • Slower sales growth

    • Promotional activity will be moderated

    • People will return to their doctors as the economy recovers

    Generic drugs expectations
    Generic Drugs Expectations

    • Greater use of generic drugs as baby boomers retire and receive a fixed income

    • A significant amount of brand name drugs are expected to come off of patent between 2009-2011

      • Currently, WAG is in a valley

        • There were few brand name drugs coming off of patent in 2008

      • Expect a peak within the next 3 years


    • A new CEO is expected to lead Walgreens

      • Upside potential

    • Possible political effects with more affordable health care coming from different plans

    Valuation dcf analysis
    Valuation – DCF Analysis

    • Cost of equity = 7.6%

    • Cost of debt = 5.36%

    • Wacc = 7.35%

    • Long term growth = 3%

    • Stock Price = 23.55

    Comparable s data
    Comparable’s data

    • Strong profitability margins; expected decline over 5 years

    • Strong Return on Equity, Return on Asset numbers; expected decline

    • Implied growth through PEG ratio lower than industry average

    • P/E ratio is lower than market and industry average

    Eva analysis
    EVA Analysis

    • Strong Return on Average Invested Capital, expected decline going forward


    • Hold the stock at this price. People have over-reacted and this has pushed the stock price down. Company is well positioned as compared to it’s peers

    • New CEO could put the company back on track.